Milestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg, LLC in New Jersey
Milestone Scientific (NYSE: MLSS) has announced that InfiniSurg, , a New Jersey-based ambulatory surgery center, has adopted its CompuFlo® Epidural System for clinical practice. The system will be operated by Dr. Roman Kosiborod, DO, who brings over 20 years of experience in interventional pain management and ambulatory anesthesia.
The order was received through Milestone's distributor, Axial Biologics. The CompuFlo® system utilizes Dynamic Pressure Sensing Technology® to precisely identify the epidural space, providing real-time visual and audible feedback during needle placement. This technology aims to reduce complications such as dural puncture while improving procedural efficiency and patient safety.
Milestone Scientific (NYSE: MLSS) ha annunciato che InfiniSurg, un centro di chirurgia ambulatoriale con sede nel New Jersey, ha adottato il suo CompuFlo® Epidural System per la pratica clinica. Il sistema sarà gestito dal Dr. Roman Kosiborod, DO, che porta con sé oltre 20 anni di esperienza nella gestione del dolore interventistico e nell'anestesia ambulatoriale.
L'ordine è stato ricevuto tramite il distributore di Milestone, Axial Biologics. Il sistema CompuFlo® utilizza la Dynamic Pressure Sensing Technology® per identificare con precisione lo spazio epidurale, fornendo un feedback visivo e sonoro in tempo reale durante il posizionamento dell'ago. Questa tecnologia mira a ridurre le complicazioni come la puntura durale, migliorando al contempo l'efficienza della procedura e la sicurezza del paziente.
Milestone Scientific (NYSE: MLSS) ha anunciado que InfiniSurg, un centro de cirugía ambulatoria con sede en Nueva Jersey, ha adoptado su CompuFlo® Epidural System para la práctica clínica. El sistema será operado por el Dr. Roman Kosiborod, DO, quien aporta más de 20 años de experiencia en el manejo del dolor intervencionista y la anestesia ambulatoria.
El pedido fue recibido a través del distribuidor de Milestone, Axial Biologics. El sistema CompuFlo® utiliza la Dynamic Pressure Sensing Technology® para identificar con precisión el espacio epidural, proporcionando retroalimentación visual y audible en tiempo real durante la colocación de la aguja. Esta tecnología tiene como objetivo reducir complicaciones como la punción dural, al mismo tiempo que mejora la eficiencia del procedimiento y la seguridad del paciente.
Milestone Scientific (NYSE: MLSS)는 뉴저지에 본사를 둔 외래 수술 센터인 InfiniSurg가 CompuFlo® Epidural System을 임상 실습에 채택했다고 발표했습니다. 이 시스템은 20년 이상의 중재적 통증 관리 및 외래 마취 경험을 보유한 Roman Kosiborod 박사(DO)가 운영합니다.
주문은 Milestone의 유통업체인 Axial Biologics를 통해 접수되었습니다. CompuFlo® 시스템은 Dynamic Pressure Sensing Technology®를 사용하여 경막외 공간을 정확하게 식별하며, 바늘 삽입 중 실시간 시각 및 청각 피드백을 제공합니다. 이 기술은 경막 천공과 같은 합병증을 줄이는 동시에 절차의 효율성과 환자 안전성을 향상시키는 것을 목표로 합니다.
Milestone Scientific (NYSE: MLSS) a annoncé qu'InfiniSurg, un centre de chirurgie ambulatoire basé dans le New Jersey, a adopté son CompuFlo® Epidural System pour la pratique clinique. Le système sera utilisé par le Dr Roman Kosiborod, DO, qui possède plus de 20 ans d'expérience en gestion de la douleur interventionnelle et en anesthésie ambulatoire.
La commande a été reçue par l'intermédiaire du distributeur de Milestone, Axial Biologics. Le système CompuFlo® utilise la Dynamic Pressure Sensing Technology® pour identifier avec précision l'espace épidural, fournissant un retour visuel et sonore en temps réel lors du placement de l'aiguille. Cette technologie vise à réduire les complications telles que la ponction durale tout en améliorant l'efficacité de la procédure et la sécurité du patient.
Milestone Scientific (NYSE: MLSS) hat angekündigt, dass InfiniSurg, ein ambulantes chirurgisches Zentrum mit Sitz in New Jersey, sein CompuFlo® Epidural System für die klinische Praxis übernommen hat. Das System wird von Dr. Roman Kosiborod, DO, betrieben, der mehr als 20 Jahre Erfahrung im Bereich der interventionellen Schmerztherapie und der ambulanten Anästhesie mitbringt.
Die Bestellung wurde über den Distributor von Milestone, Axial Biologics, entgegengenommen. Das CompuFlo®-System nutzt die Dynamic Pressure Sensing Technology®, um den epiduralen Raum präzise zu identifizieren und bietet während der Nadelplatzierung Echtzeit- visuelles und akustisches Feedback. Diese Technologie zielt darauf ab, Komplikationen wie die dura-Punktion zu reduzieren und gleichzeitig die Effizienz des Verfahrens und die Sicherheit des Patienten zu verbessern.
- Expansion of market presence through new adoption in New Jersey healthcare facility
- Distribution partnership with Axial Biologics showing active sales channels
- Technology validation from experienced medical professional with 20+ years expertise
- None.
Insights
This announcement represents incremental commercial progress for Milestone Scientific's CompuFlo® Epidural System. The adoption by InfiniSurg, a single ambulatory surgery center in New Jersey, provides a positive data point in MLSS's commercialization efforts, though the financial impact is likely minimal relative to the company's
The deal demonstrates several positive aspects: (1) functioning distribution channels, with the order coming through Milestone's distributor Axial Biologics; (2) clinical validation from Dr. Kosiborod, an experienced physician who specifically cited the technology's ability to "enhance procedural confidence and reduce complications"; and (3) continued execution of the company's stated strategy to establish CompuFlo® as the standard of care.
However, investors should recognize this as a modest win rather than a transformational development. Without disclosed financial terms or unit volumes, we can reasonably assume this represents a small portion of Milestone's annual revenue potential. For meaningful financial impact, the company would need to demonstrate accelerating adoption rates and penetration into larger healthcare systems.
The CompuFlo® technology addresses legitimate clinical needs in epidural procedures through its Dynamic Pressure Sensing Technology®, potentially reducing complications like dural puncture. This value proposition remains sound, but individual center adoptions represent early steps in what needs to be a broader commercialization journey for a company trading under
Dr. Roman Kosiborod, DO to Utilize CompuFlo® for Enhanced Precision in Pain Management Procedures
ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced anesthesiologist and pain management physician. This order was received through Milestone’s distributor, Axial Biologics.
Dr. Kosiborod brings over two decades of expertise in interventional pain management and ambulatory anesthesia. He is the Managing Director at Comprehensive Pain Management and Anesthesia and has held leadership positions across multiple healthcare organizations. Dr. Kosiborod specializes in minimally invasive procedures for spinal pain, including epidural injections, medial branch blocks, radiofrequency ablation, and spinal cord stimulation.
“We are excited to integrate the CompuFlo® Epidural System at InfiniSurg,” stated Dr. Kosiborod. “The system’s objective pressure sensing technology provides real-time feedback, which enhances procedural confidence and may reduce complications associated with traditional epidural placement. This technology aligns with our mission of delivering safer and more effective care to our patients.”
InfiniSurg, LLC is recognized for its patient-centric approach and commitment to innovation in outpatient surgical care. The addition of CompuFlo® reflects InfiniSurg’s focus on leveraging advanced technologies to optimize outcomes and procedural safety.
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, “We are pleased to welcome Dr. Kosiborod and InfiniSurg to the growing number of institutions adopting our CompuFlo® Epidural System. This further validates our technology's value proposition and supports our broader strategy to establish CompuFlo® as the new standard of care for epidural procedures.”
The CompuFlo® Epidural System is designed to precisely identify the epidural space using Dynamic Pressure Sensing Technology®, potentially reducing the risk of dural puncture and other complications. The technology provides both visual and audible feedback to aid clinicians in needle placement, improving procedural efficiency and patient safety.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
What is the latest adoption of MLSS's CompuFlo® Epidural System?
How does the CompuFlo® Epidural System enhance patient safety?
Who will be operating MLSS's CompuFlo® system at InfiniSurg?
Which distributor facilitated the CompuFlo® system order for InfiniSurg?
